ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce ...
We focus on developing pioneering and novel peptide drugs in specialist therapeutic areas
ImmuPharma PLC is an AIM listed (LSE:IMM) evolving speciality Bio-pharma company that discovers and develops peptide-based therapeutics. The Company is headquartered in London with its research team, ImmuPharma Biotech, based in Bordeaux, France.
The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus.
Preclinical analysis suggests therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action, based on the P140 platform technology.
ImmuPharma and Avion Pharmaceuticals have an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 2/3 adaptive study for Lupuzor™ and commercialise in the US.
4 core lead assets, 2 at late clinical stage
Phase 2/3 adaptive study (pivotal)
Phase 2/3 adapative (pivotal)
Why Invest in ImmuPharma?
- A rich portfolio with 2 highly attractive late-stage clinical indications – Lupus & CIDP (Both entering Phase 2/3 adaptive studies)
- Near-term business development opportunities across all programs
- Innovative peptide platform within P140 targeting a number of exciting autoimmune diseases
Public Relations & Investor Relations
Evelyn Partners, 45 Gresham St,
London EC2V 7BG
BDB Pitmans LLP
Badertscher Rechtsanwälte AG
McCarter & English, LLP, Connecticut, USA
Cabinet Regimbeau, Paris, France
Grosset-Fournier & Demachy, Paris, France
Under contract with a leading manufacturer in the peptides field